Publications of IMAkinib program


The scientific teams of Oncodesign, Cyclopharma, and their collaborators within the IMAkinib® program published recently their results during international meetings. These poster publications presented the synthesis of a radiotracer targeting the EGFR kinase, and the preclinical development of the molecule:

  • European Association of Nuclear Medicine (EANM, October 2018, Dusseldorf, Germany)

Phase 0/1 of PET imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non small cell lung cancer


  • International Symposium on Radiopharmaceutical Sciences (ISRS, May 2017, Dresden, Germany)

Radiosynthesis of the first [18F]-Nanocyclix® TKI-PET radiotracer targeting activated EGFR positive lung tumors


  • American Association for Cancer Research (AACR, April 2017, Washington DC, USA)

Preclinical proof of concept for the first [18F]-Nanocyclix® TKI-PET radiotracer targeting activated EGFR positive lung tumors


  • International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC, August 2017, Vienna, Austria)

Application of the Nanocyclix® technology to identify clinically relevant PET 


  • European Association of Nuclear Medicine (EANM, October 2017, Vienna, Austria)

In vitro and in vivo evaluation of two enantiomers of Nanocyclix® EGFR targeted PET radiotracer


The first radiotracer developed within IMAkinib® program has been succesfully evaluated in phase 0/1 clinical trial (first in-man phase 0/I clinical trial NCT02847377). The objective of this clinical phase was to determine the molecule biodistribution in patients, and confirm its specific binding in tumors harboring EGFR mutation in comparison with EGFR non-mutated tumors. This clinical study highlights the expertise of our partners as it is the first phase 0 performed at the center of early investigation within the Georges François Leclerc Centre and the first production of a radiotracer dedicated to clinical research done by Cyclopharma in the radiochemistry laboratory of Pharm’image.


These concrete achievements represent the results  from the last 10 years research investments carried out on pharmaco-imaging development within the Pharm’image biocluster with all actors, from chemistry to clinic, involved in new radiopharmaceutical drug development within Pharm’image.


A complete presentation of this radiotracer development, including the clinical trial design, is also available on Oncodesign website: